top of page
  • Writer's pictureBrooks Hill Partners

Brooks Hill Partners Invests in Cellbricks

Brooks Hill Partners has invested in Cellbricks, a Berlin-based startup leveraging a novel suite of 3D bioprinting technologies to transform preclinical pharmaceutical research and clinical care. Cellbricks will soon enter preclinical trials for its 3D bioprinted personalized post-mastectomy breast reconstruction implant.

Learn more about Cellbricks here.

Interested in learning more?

Are you a health tech founder?

bottom of page